Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic ...

SHANGHAI & INDIANAPOLIS, June 05, 2025--(BUSINESS WIRE)--Acerand Therapeutics, a clinical-stage biotech company focusing on the discovery and development of innovative small-molecule therapies in ...

A phase 1b study of PSCA CAR T cells plus or minus radiation for the treatment of patients with PSCA+ metastatic castration-resistant prostate cancer. This is an ASCO Meeting Abstract from the 2024 ...

Merck & Co. is expanding a research partnership with Orion into an exclusive licensing pact, putting more than $1.6 billion biobucks on the table for cancer candidates targeting CYP11A1, an enzyme ...

Haisco Pharmaceutical Group Co. Ltd. has divulged cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of cancer.

Xuanzhu Pharma Co. Ltd. has divulged cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of castration-resistant prostate cancer.

Characteristics and outcomes of patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) showing a primary resistance (PR) to docetaxel (DOC): Results from a large real-world ...

Researchers have identified an enzyme that is essential to the allergic reaction to peanuts. Blocking the enzyme's activity in sensitized mice prevented diarrhea and inflammation, and reduced levels ...

First published in the Journal of the Endocrine Society in 2019, the paper has recently been featured by the American Endocrine Society as part of Adrenal Awareness Month. In the study researchers ...

Acerand Therapeutics Initiates First-in-Human Phase I Clinical Trial of ACE-232, a Novel CYP11A1 Inhibitor for Advanced Prostate Cancer Acerand Therapeutics, a clinical-stage biotech company focusing ...